The test reports on the G84E mutation in the HOXB13 gene, which studies have shown increase a person’s risk of developing prostate cancer.
The company plans to use the funding to expand its commercial team, scale operations and develop new products.
The UAE-based asset owner and investor has announced it is to consolidate several healthcare companies within Pure Health.
During a panel at CES, leaders at digital therapeutic companies discuss the state of the market right now and what’s needed to boost adoption.
